( August 3, 2026, 4:35 PM EDT) -- NEW YORK — The false marketing claims asserted by consumers against manufacturers of cold medications containing oral phenylephrine (PE) that labeled the medications as "Maximum Strength" or "Max Strength" when they were no more effective than any other oral nasal decongestant are not expressly preempted by federal law, the Second Circuit U.S. Court of Appeals held, partially reversing a decision by the multidistrict litigation judge who had dismissed all claims with prejudice....